Across TCGA pan-cancer cohorts, ABHD16A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ABHD16A data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABHD16A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABHD16A expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, COAD, and HNSC are the cancer types where ABHD16A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.468	0.751	.013	10	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
HNSC	OS	Quartile	II,III,IV	0.846	0.565	.016	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ABHD16A tumor-vs-normal RNA expression · all ABHD16A data types